Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Q Biomed Inc (QBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 41,818
  • Shares Outstanding, K 14,080
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,540 K
  • 36-Month Beta 1.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 22.17
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.31
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 10/17/18
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 08/31/18
See More
  • Average Estimate -0.26
  • Number of Estimates 2
  • High Estimate -0.24
  • Low Estimate -0.29
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +29.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6700 +77.84%
on 08/24/18
3.0700 -3.26%
on 09/21/18
+1.2600 (+73.68%)
since 08/21/18
3-Month
1.6700 +77.84%
on 08/24/18
3.6000 -17.50%
on 07/09/18
-0.4900 (-14.16%)
since 06/21/18
52-Week
1.6700 +77.84%
on 08/24/18
5.9000 -49.66%
on 11/30/17
-1.0000 (-25.19%)
since 09/21/17

Most Recent Stories

More News
Q Biomed Inc. Announces Dr. Rajendra Apte Joins Advisory Board

NEW YORK , Sept. 17, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that Rajendra Apte , MD, PhD has...

QBIO : 2.9700 (-0.34%)
Q Biomed Inc. Announces Dr. Rajendra Apte Joins Advisory Board

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that Rajendra Apte, MD, PhD has joined its Advisory Board contributing his extensive...

QBIO : 2.9700 (-0.34%)
Q BioMed Inc. Announces FDA Filing for Strontium Chloride Sr89 Injection USP for Relief of Metastatic Cancer Bone Pain

QBIO : 2.9700 (-0.34%)
Q Biomed Inc. Extends its Exclusive Option Agreement With Washington University in St. Louis for a Novel Companion Biomarker for Monitoring Glaucoma and Initiates a Clinical Study

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that it is extending its option agreement with Washington University in St. Louis....

QBIO : 2.9700 (-0.34%)
Q Biomed Inc. to Present at the Microcap Conference Taking Place April 9-10 at the Essex House in New York City

NEW YORK , April 5, 2018 /PRNewswire/ --

QBIO : 2.9700 (-0.34%)
Q Biomed Inc. to Present at the Microcap Conference Taking Place April 9-10 at the Essex House in New York City

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, announced today that Denis Corin, Chief Executive Officer, will present at the MicroCap Conference being held at the...

QBIO : 2.9700 (-0.34%)
Significant Progress in Non-opioid Therapy Picks up Steam as Market Projected to Reach $22 Billion by 2022

MarketNewsUpdates.com News Commentary

SRNE : 4.30 (-3.37%)
QBIO : 2.9700 (-0.34%)
DRRX : 1.07 (-2.73%)
PTI : 2.58 (+4.88%)
VRTX : 180.08 (-0.24%)
Q Biomed Inc. Announces FDA Filing for Approval of a New Manufacturing Facility for Non-Opioid Strontium Chloride SR89 Injection USP for Relief of Cancer Bone Pain

NEW YORK , March 16, 2018 /PRNewswire/ --

QBIO : 2.9700 (-0.34%)
Q Biomed Inc. Announces FDA Filing for Approval of a New Manufacturing Facility for Non-Opioid Strontium Chloride SR89 Injection USP for Relief of Cancer Bone Pain

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, and Bio-Nucleonics, licensor of Strontium 89 Chloride, announce submission of a regulatory filing to the...

QBIO : 2.9700 (-0.34%)
Q BioMed Inc. to Present at 30th Annual Roth Conference, Taking Place March 11-14, 2018, in Dana Point, CA

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, announced today that Denis Corin, Chief Executive Officer will present at the 30th Annual Roth Conference, being held...

QBIO : 2.9700 (-0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade QBIO with:

Key Turning Points

2nd Resistance Point 3.1167
1st Resistance Point 3.0433
Last Price 2.9700
1st Support Level 2.9233
2nd Support Level 2.8767

See More

52-Week High 5.9000
Fibonacci 61.8% 4.2841
Fibonacci 50% 3.7850
Fibonacci 38.2% 3.2859
Last Price 2.9700
52-Week Low 1.6700

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar